Literature review · Metabolism & weight

Cagrilintide

Human studies investigate the amylin analogue alone and in combination with semaglutide. A combination's result must not be presented as the isolated effect of cagrilintide.

By HeartPep · Reviewed · 5 selected source records

Buy from HeartPep.com

Laboratory research only. Not for human or veterinary use.

At a glance

A dose-finding phase 2 trial directly studied cagrilintide. REDEFINE 1 later compared a combination, its components and placebo, with the main comparison focused on the combination.

Identity & scope

Cagrilintide is a long-acting amylin analogue. Cagrilintide alone and the cagrilintide-semaglutide combination are different study interventions.

Catalogue labels covered: Cagrilintide.

What the research shows

  • The phase 2 trial reported greater average weight reduction than placebo over 26 weeks, together with gastrointestinal adverse events [1].
  • REDEFINE 1 supports conclusions about its studied combination, not an assumption that every combination benefit is attributable to cagrilintide alone [2].
  • REDEFINE 9 adds two lower-strength clinical combination arms versus placebo, without an isolated cagrilintide arm [5].

Critical interpretation

A combination result is not a monotherapy result

REDEFINE 1 contains component arms, but its main headline comparison is the combination against placebo. Reporting that number as the effect of cagrilintide alone would remove a second active compound from the intervention being described. The earlier dose-finding study is more direct evidence for cagrilintide monotherapy, although it is shorter and smaller. Interpretation should also preserve which estimand is reported: an estimate assuming adherence answers a different question from an estimate retaining outcomes after discontinuation. This is a reason to inspect the statistical plan, not to select whichever percentage appears largest. [1] [2]

New diabetes evidence introduces another endpoint and a correction

The 2026 REIMAGINE 2 study examines glycaemic control in a population receiving background diabetes treatment. Its primary HbA1c comparison cannot be substituted for a weight-management endpoint or for cagrilintide monotherapy efficacy. The linked published correction also belongs in the reading trail. Because its text was not retrieved in this review, numerical results from that report are withheld rather than assuming what changed. A correction is distinct from an expression of concern or retraction; the record should prompt examination of the corrected paper without making an unsupported judgement about its validity. [3] [4]

REDEFINE 9 studied a specific combination

The study randomised adults to the two combination regimens or placebo within a dose level. The similar point estimates do not establish that the regimens are equivalent. The results cannot isolate either ingredient’s contribution or validate another preparation. [5]

Limitations & uncertainties

  • No selected trial tested a HeartPep vial or nasal formulation, or confirmed commercial batch comparability.
  • Study phase, population, analysis strategy and the exact intervention matter. These sources do not establish a catalogue product as a clinical medicine.

Open research questions

  • What is the independently replicated contribution of each component in combination studies?
  • What do longer-term outcome and safety data show for cagrilintide alone?

Selected papers & source records

Download bibliography
Human studyNamed compoundAbstract / record checked

1. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial (opens in a new tab)

Lau DCW, Erichsen L, Francisco AM, et al. (2021). The Lancet. DOI: 10.1016/S0140-6736(21)01751-7 (opens in a new tab) · PMID 34798060

Design & population
26-week dose-finding trial with 706 randomized participants, without diabetes, including placebo and liraglutide comparisons.
What the study found
Mean weight reduction across cagrilintide groups was approximately 6.0%-10.8%, versus 3.0% with placebo under the trial-product estimand. Gastrointestinal events were more frequent than with placebo.
Limits on interpretation
Phase 2 and manufacturer-funded; follow-up and population are limited. The results do not validate catalogue formulations.
Human studyRelated preparationAbstract / record checked

2. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (opens in a new tab)

Garvey WT, Blüher M, Osorto Contreras CK, et al.; REDEFINE 1 Study Group (2025). New England Journal of Medicine. DOI: 10.1056/NEJMoa2502081 (opens in a new tab) · PMID 40544433

Design & population
68-week phase 3a randomized trial in 3,417 adults, including combination, individual-component and placebo groups.
What the study found
The main combination-versus-placebo comparison reported mean weight changes of -20.4% and -3.0%, with substantially more gastrointestinal events in the combination group.
Limits on interpretation
The headline comparison concerns two compounds together. It is not an estimate of cagrilintide alone or of the effect of a commercial research product.
Human studyRelated preparationAbstract / record checked

3. Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study (opens in a new tab)

Buse JB, Bajaj HS, Dalskov SM, et al.; REIMAGINE 2 study group (2026). The Lancet Diabetes & Endocrinology. DOI: 10.1016/S2213-8587(26)00125-7 (opens in a new tab) · PMID 42251859

Design & population
68-week trial in 2,713 adults with inadequately controlled type 2 diabetes; combination and component arms were included.
What the study found
The primary comparison concerns HbA1c with the combination versus semaglutide, rather than a stand-alone cagrilintide weight-loss estimate.
Limits on interpretation
A published correction is linked, PMID42320507. Its full text was not retrieved here, so numerical effect estimates are not reproduced. The trial is manufacturer-funded.
Technical referenceRelated preparationBibliographic record checked

4. Correction to Lancet Diabetes Endocrinol 2026; published online June 7. https://doi.org/10.1016/S2213-8587(26)00125-7 (opens in a new tab)

The Lancet Diabetes & Endocrinology, no named author listed in PubMed (2026). The Lancet Diabetes & Endocrinology. DOI: 10.1016/S2213-8587(26)00157-9 (opens in a new tab) · PMID 42320507

Design & population
Published erratum linked to the REIMAGINE 2 primary report.
What the study found
The primary bibliographic record verifies the correction linkage.
Limits on interpretation
No abstract available; the correction text was not reviewed. Its existence alone establishes neither that the results were invalid nor that all quantitative results remained unchanged.
Human studyRelated preparationAbstract / record checked

5. Efficacy and safety of co-administered cagrilintide-semaglutide (CagriSema) 1·7 mg each and 1·0 mg each in adults with overweight or obesity (REDEFINE 9): a multicentre, randomised, double-blind within-dose-level, placebo-controlled, parallel-group, phase 3b trial (opens in a new tab)

Wharton S, Broholm C, Horn D, et al. (2026). The Lancet Diabetes & Endocrinology. DOI: 10.1016/S2213-8587(26)00275-5 (opens in a new tab) · PMID 43033821

Design & population
REDEFINE 9 (NCT06388187), a randomized phase 3b trial of two subcutaneous cagrilintide–semaglutide combinations versus placebo in 309 adults without diabetes. Published 14 November 2026.
What the study found
At week 68, the efficacy analysis estimated placebo-adjusted differences in weight change of −18.8 and −19.0 percentage points. Adverse events were common in all arms, mostly mild or moderate and gastrointestinal.
Limits on interpretation
Sponsor-funded. There was no single-component arm. The primary comparisons each tested an active regimen against placebo. Publisher abstract and accessible excerpts consulted.

Search & review scope

Targeted PubMed and publisher check of new and existing combination evidence.. Checked 16 November 2026.

Selected phase 2 monotherapy, phase 3a obesity combination and 2026 diabetes combination studies, with the linked REIMAGINE 2 correction record. Reviewed the REDEFINE 9 publisher abstract and accessible article excerpts.

REDEFINE 9 was assessed from the publisher abstract and excerpts. The existing correction to REIMAGINE 2 remains linked. The selected trials do not cover all preparations or outcomes.

Recorded search terms
  • site.pubmed.ncbi.nlm.nih.gov/34798060 Cagrilintide
  • site.pubmed.ncbi.nlm.nih.gov cagrilintide REDEFINE 1 2025
  • site.pubmed.ncbi.nlm.nih.gov/40544433 3417
  • site.pubmed.ncbi.nlm.nih.gov cagrilintide phase 3 2026
  • site.pubmed.ncbi.nlm.nih.gov 42251859 Authors
  • site.pubmed.ncbi.nlm.nih.gov 42320507 Correction
  • PMID 43033821 / DOI 10.1016/S2213-8587(26)00275-5

Read the collection’s methods and editorial limits. For formal research, assess and cite the original paper.

Cite this review

HeartPep. Cagrilintide: literature review. HeartPep literature library. Reviewed 16 November 2026. https://heartpep.com/uk/research/library/cagrilintide.

HeartPep is the commercial publisher of this secondary summary. It is not a peer-reviewed primary paper. Cite the original studies for their findings.

Buy from HeartPep.com

Laboratory research only. Not for human or veterinary use.

← All reviews and reference notes